Market Access | pharmaphorum

News

FDA sets new decision date for Ipsen’s FOP therapy

US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.

News

UK Chancellor’s budget welcomed by biopharma sector

Industry groups are happy with news on R&D tax credits, funding for MHRA, and investment zones.

News

Novo Nordisk shadows Lilly with insulin price cut plan

Danish drugmaker says it will reduce the price of its insulin products in the US by up to 75%.

Market Access

The female force behind healthcare innovation

Passionate, effective, and forward-thinking female leaders are critical to driving innovation.

News

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

Department of Veterans Affairs will cover the drug for veterans with early-stage Alzheimer's.

News

Intercept will have to face FDA advisors for NASH drug

Shares in the company slump as it reveals an FDA advisory committee has been set for 19th May.

News

Pfizer’s migraine push builds with Zavzpret nod

Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.

News

Despite FDA doubts, advisors back first-line Polivy use

Panel votes 11 to 2 to back Roche's drug for treatment-naïve diffuse large B-cell lymphoma.

News

FDA sets new decision date for Ipsen’s FOP therapy

US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.

News

Novo Nordisk shadows Lilly with insulin price cut plan

Danish drugmaker says it will reduce the price of its insulin products in the US by up to 75%.

Press Releases

News

Solid Biosciences acquires AavantiBio, conducts $75 million ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a

News

AstraZeneca pays record 660% premium for gene editing compan...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately

Views & Analysis

Market Access

The female force behind healthcare innovation

Passionate, effective, and forward-thinking female leaders are critical to driving innovation.

Market Access

Are we entering a new era of blockbuster weight-loss drugs?

Has the industry found a new revenue driver in weight-loss treatments?

Deep Dive

Market Access

eyeforpharma 2020: Redefining value for COVID-19 and beyond

The coronavirus pandemic was front and centre of everyone’s minds at this year’s spring eyeforpharma conferences – not least because the usual locations of Barcelona and Philadelphia had been swapp

Market Access

ICSs: improving patient and market access at a local level

Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more joined-up services for their locality in England from 1 July 2022 – will tou

Market Access

Time is motor neurons – the importance of newborn screening ...

Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and irreversible loss of motor neuro

Webinars

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Exploring a united vision for British pharma at Anthropy - t...

Anthropy 2022 brought climate change to industry in Cornwall in (a very wet and windy) early November, settling cosily into the truly eco-minded environs of the Eden Proje

Market Access

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaph...

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With RNA-based technology hitti

White Papers

Debates & Insight

Sponsored

Computer Gaming: The Future of Decision-Making for Life Scie...

How can life science brands identify winning strategic decisions when there are so many variables to consider?

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Events

Partner Content

SMi’s 5th Annual 3D Cell Culture Virtual Conference

3D Cell Culture

Partner Content

Patient and market insights from leading KOLs and life scien...

Insights from leading KOLs in new Dermatology eBook

Partner Content

Is there a faster way to build clinical trials?

Easier and faster Clinical Trials with Clinical MDR.

FDA sets new decision date for Ipsen’s FOP therapy

UK Chancellor’s budget welcomed by biopharma sector

Novo Nordisk shadows Lilly with insulin price cut plan

The female force behind healthcare innovation

First major insurer covers Eisai’s Alzheimer’s drug Leqembi

Intercept will have to face FDA advisors for NASH drug

Pfizer’s migraine push builds with Zavzpret nod

Despite FDA doubts, advisors back first-line Polivy use

FDA sets new decision date for Ipsen’s FOP therapy

Novo Nordisk shadows Lilly with insulin price cut plan

Solid Biosciences acquires AavantiBio, conducts $75 million ...

AstraZeneca pays record 660% premium for gene editing compan...

The female force behind healthcare innovation

Are we entering a new era of blockbuster weight-loss drugs?

eyeforpharma 2020: Redefining value for COVID-19 and beyond

ICSs: improving patient and market access at a local level

Time is motor neurons – the importance of newborn screening ...

Innovative Medicines Fund and the opportunity for ICSs to mo...

Medical Informatics and Rare Disease: a bridge between two w...

ICSs - an opportunity to improve Patient & Market Access at ...

Exploring a united vision for British pharma at Anthropy - t...

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaph...

Computer Gaming: The Future of Decision-Making for Life Scie...

Innovative contracting in Europe – a Trojan horse?

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

SMi’s 5th Annual 3D Cell Culture Virtual Conference

Patient and market insights from leading KOLs and life scien...

Is there a faster way to build clinical trials?

Could Daiichi Sankyo have another ADC winner in cancer?

An inside guide to unlocking clinical research in the UK

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Clinical
--Sustainability
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Future of Generics
-Understanding HCPs
-The Future of Generics

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

White Papers

Debates & Insight

Partner Content

Editor's Picks